Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 4,268 |
|
|||||
| News | - |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| SAB Biotherapeutics Inc | SABSW | NASDAQ | Equity Warrant |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0195 | -27.86% | 0.0505 | 11:09:25 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.085 | 0.0505 | 0.085 | 0.07 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume |
|---|---|---|---|---|
| 20 | 4,268 | 0.0717308 | 306 | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:02:47 | 350 | 0.0505 | USD |
SAB Biotherapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.66M | 52.32M | - | 2.24M | -42.19M | -0.81 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News SAB Biotherapeutics
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
SABSW Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| SAB BIO is a clinical-stage biopharmaceutical company working to treat and prevent immune and autoimmune disorders. Founded in 2014 and traded on NASDAQ (SABS) since 2021, SAB BIO's innovative genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma. The science behind the platform originated in 1998, and the company began its first clinical trials in 2017. To date, SAB BIO has conducted seven clinical trials that have dosed 700 individuals across multiple therapeutic areas. The safety and immunogenicity database for these trials shows zero patients with serum sickness or neutralizing anti-drug antibodies, which suggests an improved safety profile over other therapies. |
